News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CMBI Elevates THENLIUS (02696.HK) TP to $61.98, Expects Large Potential in Innovative Drug R&D
HENLIUS (02696.HK) has the capability to evolve from a profitable biosimilar company into a leading enterprise in the biologics sector, CMBI published a research report saying. The...
Reset
Send
The window will close in 5 seconds
<Research>CMBI Elevates THENLIUS (02696.HK) TP to $61.98, Expects Large Potential in Innovative Drug R&D
Close
Recommend
2
Positive
2
Negative
1
 
SHORT SELL
 
STOCK INFO

HENLIUS (02696.HK)  -0.500 (-0.787%)    Short selling $641.93K; Ratio 2.776%   has the capability to evolve from a profitable biosimilar company into a leading enterprise in the biologics sector, CMBI published a research report saying.

The clinical data of several innovative drugs under R&D, including HLX43, HLX22 and Serplulimab, have shown promising results, suggesting substantial development potential. Therefore, the broker elevated its target price from $20.33 to $61.98, with rating kept at Buy.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-18 16:25.)

Related NewsBOCOMI Bullish on Innovative Pharma Sector, Expects CN Commercial Insurance Innovative Drug List to Drive 10x+ Growth in Related Payments in LT

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.